PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
20.15
Positive P/E while Medical - Pharmaceuticals median is negative at -3.73. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
2.94
P/S less than half the Medical - Pharmaceuticals median of 12.06. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
4.64
P/B 1.25-1.5x Medical - Pharmaceuticals median of 3.45. Guy Spier would scrutinize if premium reflects better asset utilization.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.64
Fair value ratio 1.25-1.5x Medical - Pharmaceuticals median of 3.45. Guy Spier would scrutinize if premium reflects durable advantages.
1.24%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
No Data
No Data available this quarter, please select a different quarter.